Oriola Corp Class B · OMXHEX:ORIOLA
Oriola Corp Class B — Q2 2025 Earnings Presentation
23 slides from Oriola Corp Class B's earnings presentation, Jul 18, 2025
Slide 1: Half-Year Report January-June 2025
Half-Year Report January-June 2025 18 July 2025
Slide 2: Disclaimer
Disclaimer The following applies to this presentation, the oral presentation of the information in this presentation by Oriola Corporation (the “Company” or “Oriola”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “In
Slide 3: Agenda
Agenda 1 Q2 2025 highlights 2 Operating environment 3 Segments 4 Financial review Q&A 18 JULY 2025
Slide 4: Strong partnerships drive Distribution growth and profitability
Strong partnerships drive Distribution growth and profitability • Sales growth supported by both segments. • Sales margin improvement from Distribution segment, especially Q2 25 services. Net sales • Adjusted EBITDA slightly above previous year despite higher costs. 494 (439) +12% • ERP project proc
Slide 5: Operating environment
Operating environment • Value of the pharmaceutical distribution market grew in both Sweden and Finland. • Consumer confidence weak in both Finland and Sweden. • Cost inflation has slowed down, with more normalised energy and fuel prices. • The challenges in the availability of pharmaceuticals conti
Slide 6: Q2: Distribution segment
Q2: Distribution segment • Net sales grew 11% to EUR 398 high peaks in orders resulting in extra (358) million. costs. • Growth was particularly strong in • Strategic focus to enhance customer Sweden. centricity to build strong partnerships. • Across the whole segment, growth • Successful onboarding
Slide 7: Q2: Wholesale segment
Q2: Wholesale segment • Net sales grew 18% to EUR 96 (82) • In Q2, sale of seasonal products such million. as sun care and allergy products, and • Growth primarily driven by wholesale insect repellents, negatively impacted business in Sweden, supported by by the weather. good development in parallel
Slide 8: Oriola's science-based climate targets
Oriola’s science-based climate targets Oriola’s science-based targets have been approved by the Science Based Targets initiative (SBTi). Reflects our strong commitment to long-term sustainability and responsible business practices. Oriola’s targets are: • Oriola commits to reach net-zero greenhouse
Slide 9: Financial review
Financial review 18 JULY 2025
Slide 10: Invoicing and net sales
Invoicing and net sales Invoicing and net sales EUR million 1,073 Invoicing 2,073 Invoicing 4-6 2025 952 1,861 • Invoicing and net sales growth was driven by both Distribution and +13% +11% Wholesale segments. 1-6 2025 • Invoicing and net sales growth was largely driven by the Distribution segment.
Slide 11: Sales margin
Sales margin Sales margin EUR million +5% 83.5 79.7 4-6 2025 • Sales margin improvement of 6% driven by the Distribution +6% segment, especially in services. 42.2 42.4 39.7 41.3 40.0 37.7 1-6 2025 • Sales margin improvement driven by the Distribution segment, generated both from volume growth and ne
Slide 12: EBITDA
EBITDA Adjusted EBITDA EUR million 15.7 15.6 0.4 4-6 2025 • Adjusting items totalled EUR -6.5 (0.5) million, including EUR -3.2 million ERP investment related implementation cost, EUR -2.8 8.1 million loss from the sale of dose dispensing business in Sweden 8.0 and EUR -0.5 million other cost. 8.1 •
Slide 13: Distribution segment
Distribution segment Invoicing and net sales EUR million Adjusted EBITDA EUR million 977 Invoicing 1,889 Invoicing 871 1,698 +12% +11% 8.3 15.4 6.1 12.4 +35% +24% +11% +16% 358 398 Net sales 652 757 Net sales Q2 24 Q2 25 YTD 24 YTD 25 Q2 24 Q2 25 YTD 24 YTD 25 4-6 2025 4-6 2025 • Invoicing grew by 1
Slide 14: Wholesale segment
Wholesale segment Net sales EUR million Adjusted EBITDA EUR million 96.1 184.2 81.6 162.8 +18% +13% 6.6 4.5 3.1 -33% 2.1 -32% Q2 24 Q2 25 YTD 24 YTD 25 Q2 24 Q2 25 YTD 24 YTD 25 4-6 2025 4-6 2025 • Net sales grew by 18% to EUR 96 million • Decline in profitability related to higher operating expense
Slide 15: Profit burdened by cost related to the ERP project and impairment
Profit burdened by cost related to the ERP project and impairment related to the sale of Svensk Dos Net profit EUR million 7.5 1-6 2025 2025 -11.7 • EBITDA below last year due to higher adjusting 1-6 items. • Adjusting items totalled MEUR -8.1 (-0.4) and -4.2 -2.9 included MEUR -4.5 ERP investment r
Slide 16: Positive free cash flow
Positive free cash flow Free cash flow EUR million 1-6 2025 1-6 1-6 Abs. • EBITDA below last year due to higher adjusting EUR million 2025 2024 change items. EBITDA 7.5 15.3 -7.8 • Increase in trade payables has impacted working capital positively. Adjustments 3.3 0.0 3.3 • Taxes at last year’s leve
Slide 17: Net debt on a low level
Net debt on a low level Net interest-bearing debt EUR million Net interest-bearing debt items 30 Jun 30 Jun Abs. EUR million 2025 2024 change 9 -35.4 Bank loans (syndicated bank & term) 30.0 32.0 -2.0 -2 Commercial papers 19.9 19.8 +0.1 -9 -7 -12 Advance payment from pharmacies 10.9 14.1 -3.2 -21 Le
Slide 18: Solid financial position
Solid financial position Gearing1 and equity ratio % Gearing Equity ratio 1-6 2025 21 • The impairment and 19 19 17 17 18 15 14 write-down in Dose 13 Sweden, adjusting 5 items (mainly ERP) and the negative result from -1 Kronans Apotek had a -6 -5 negative impact on the -8 -12 net result and the equ
Slide 19: Kronans Apotek (Swedish Pharmacy Holding)
Kronans Apotek (Swedish Pharmacy Holding) 2025 2024 Change 2025 2024 Change 2024 Key figures EUR million 4-6 4-6 % 1-6 1-6 % 1-12 Net sales 313.5 291.9 7.4 608.7 578.3 5.3 1,151.1 EBITA -2.6 0.6 -1.7 -3.8 55.1 -5.9 EBITA % -0.8 0.2 -0.3 -0.7 -0.5 Adjusted EBIT -3.3 0.3 -3.1 -4.6 32.8 -8.0 Adjusted E
Slide 20: Outlook
Outlook In 2025, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of certain phar
Slide 21: Q2 25 Key takeaways
Q2 25 Key takeaways Science-based climate targets approved by SBTi Sales growth and sales margin improvement Focus in H2 on sales and sales margin – strong distribution business growth, and secure pass-through margin 18 JULY 2025
Slide 22: Our next event
Our next event 30 October 2025 Q3 2025 Interim Report Thank you for joining us!
Slide 23: Health for life